15 completed, 4 terminated, 2 withdrawn. 21 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Completed 15, Terminated 4, Withdrawn 2 |
| Phase 1 | 6 | Completed 3, Terminated 2, Withdrawn 1 |
Follow Testicular Lymphoma: new trials by email Literature Review of Testicular Lymphoma trials Research Report on Testicular Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma rituximab, lenalidomide, romidepsin - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2016-10-01 | 2016-08-11 | |
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas lenalidomide, etoposide, prednisone - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Completed | University of Chicago | 55 | 2014-07-29 | 2026-03-11 |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies cyclophosphamide, fludarabine phosphate, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 2 | Withdrawn | University of Medicine and Dentistry of New Jersey | 2014-01-01 | 2016-07-14 | |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies vorinostat, tacrolimus, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2013-06-01 | 2018-07-24 |
| Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies therapeutic allogeneic lymphocytes, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 2 | Completed | University of Chicago | 77 | 2013-04-04 | 2019-08-07 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant lenalidomide, rituximab, pharmacological study - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 3 | 2012-05-01 | 2017-07-27 |
| Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 43 | 2011-09-01 | 2017-05-19 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Bendamustine Hydrochloride, Pharmacological Study, Rituximab - Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 43 | 2011-07-01 | 2019-12-16 |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Wake Forest University Health Sciences | 16 | 2011-01-01 | 2018-09-07 |
| Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Akt inhibitor MK2206, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 60 | 2010-12-01 | 2020-11-04 |
| Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma rituximab, peripheral blood stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation - B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 63 | 2009-02-01 | 2018-01-02 |
| Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer alemtuzumab, total-body irradiation, fludarabine phosphate - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 12 | 2005-03-01 | 2017-05-30 |
| Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma rituximab, prednisone, cyclophosphamide - Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 2 | Terminated | National Cancer Institute (NCI) | 62 | 2004-12-01 | 2017-05-25 |
| MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma ipilimumab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 18 | 2004-06-01 | 2014-05-30 |
| Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer fludarabine phosphate, total-body irradiation, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 150 | 2004-04-01 | 2020-01-29 |
| Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies gemcitabine hydrochloride, carboplatin, dexamethasone - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 55 | 2003-08-01 | 2017-06-29 |
| Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma oblimersen sodium, rituximab, laboratory biomarker analysis - Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 2 | Completed | National Cancer Institute (NCI) | 48 | 2003-01-01 | 2014-05-28 |
| Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer cyclophosphamide, fludarabine phosphate, tacrolimus - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 53 | 2002-01-01 | 2017-05-17 |
| Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer total-body irradiation, fludarabine phosphate, cyclosporine - Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 21 | 2000-05-01 | 2020-01-21 |
Showing 20 of 21. Sign in to see all of them.
Lymphoma, B-Cell, Marginal Zone (21) · Lymphoma, Large B-Cell, Diffuse (21) · Waldenstrom Macroglobulinemia (21) · Intraocular Lymphoma (20) · Leukemia, Lymphocytic, Chronic, B-Cell (20) · Lymphoma, Follicular (20) · Lymphoma, Large-Cell, Immunoblastic (20) · Lymphoma, Mantle-Cell (20) · Lymphoma, Non-Hodgkin (20) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (19) · Burkitt Lymphoma (18) · Hodgkin Disease (17) · Immunoblastic Lymphadenopathy (14) · Lymphoma, Extranodal NK-T-Cell (14) · Lymphoma, Large-Cell, Anaplastic (14)
Blood Protein Disorders (21) · Cardiovascular Diseases (21) · Hematologic Diseases (21) · Hemic and Lymphatic Diseases (21) · Hemorrhagic Disorders (21) · Hemostatic Disorders (21) · Immune System Diseases (21) · Immunoproliferative Disorders (21) · Lymphatic Diseases (21) · Lymphoma (21) · Lymphoma, B-Cell (21) · Lymphoproliferative Disorders (21) · Neoplasms (21) · Neoplasms by Histologic Type (21) · Neoplasms, Plasma Cell (21)
Rituximab (9) · Cyclophosphamide (6) · Peripheral Blood Stem Cell Transplantation (6) · Whole-Body Irradiation (6) · fludarabine phosphate (6) · Cyclosporine (5) · Mycophenolic Acid (5) · Tacrolimus (4) · Lenalidomide (3) · Transplantation (3) · Busulfan (2) · Doxorubicin (2) · Methotrexate (2) · Prednisone (2) · Vincristine (2)
Fred Hutchinson Cancer Center (8) · National Cancer Institute (NCI) (6) · University of Chicago (2) · Case Comprehensive Cancer Center (1) · Mayo Clinic (1) · Northwestern University (1) · University of Medicine and Dentistry of New Jersey (1) · Wake Forest University Health Sciences (1)
United States (20) · Italy (3)
David Maloney (3) · Adam Petrich, MD (1) · Ajay Gopal (1) · Barbara Pro (1) · Brenda Sandmaier (1) · Grzegorz Nowakowski (1) · Hillard Lazarus (1) · Hongtao Liu (1) · John Gerecitano (1) · Marco Mielcarek (1) · Mary Ann Knovich, MD (1) · Mohamed Sorror (1) · Paul O'Donnell (1) · Pavan Reddy (1) · Roger Strair (1)
PMID 32499241, PMID 26213141, PMID 26764356, PMID 28314788, PMID 31481800, PMID 40720747
P30CA015704 (6), P01CA078902 (3), N01CM62202 (2), P30CA015083 (2), N01CM00039 (1), N01CM17003 (1), N01CM17107 (1), N01CM62203 (1), P01CA018029 (1), P30CA008748 (1), P30CA014599 (1), P30CA016672 (1), P30CA046592 (1), P30CA072720 (1), U01CA069856 (1)